Disruption of Iron Homeostasis to Induce Ferroptosis with Albumin‐Encapsulated Pt(IV) Nanodrug for the Treatment of Non‐Small Cell Lung Cancer
Small · 2023
DOI: 10.1002/smll.202206688 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small, 2023. Verfasst von Hui-Xiang Tian und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, 410008, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Ferroptosis, Antineoplastic Agents. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Health Commission of Hunan Province, National Natural Science Foundation of China, Hunan Cancer Hospital Climb Plan.
Abstract (Originalsprache)
Non‐small cell lung cancer (NSCLC) is the most common pathological type of lung cancer , accounting for approximately 85% of lung cancers. For more than 40 years, platinum (Pt)‐based drugs are still one of the most widely used anticancer drugs even in the era of precision medicine and immunotherapy. However, the clinical limitations of Pt‐based drugs, such as serious side effects and drug resistance, have not been well solved. This study constructs a new albumin‐encapsulated Pt(IV) nanodrug (HSA@Pt(IV)) based on the Pt(IV) drug and nanodelivery system. The characterization of nanodrug and biological experiments demonstrate its excellent drug delivery and antitumor effects. The multi‐omics analysis of the transcriptome and the ionome reveals that nanodrug can activate ferroptosis by affecting intracellular iron homeostasis in NSCLC. This study provides experimental evidence to suggest the potential of HSA@Pt(IV) as a nanodrug with clinical application.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, 410008, China.
- School of Bioscience and Bioengineering, South China University of Technology, Guangzhou, 510006, China.
- National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, 410008, China.
- Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, China.
- Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha, 410008, China.
- Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, 110 Xiangya Road, Changsha, 410008, China.
ORCID-Profile: Hui-Xiang Tian, Jie Mei, Peng-Yuan Wang, Xiang-Ping Li
Förderung
- Health Commission of Hunan Province
- National Natural Science Foundation of China
- Hunan Cancer Hospital Climb Plan
- Zhejiang Provincial Natural Science Foundation of China
Zitieren
APA
Tian, H. X., Mei, J., Cao, L., Song, J., Rong, D., Fang, M., Xu, Z., Chen, J., Tang, J., Xiao, H., Liu, Z., Wang, P. Y., Yin, J. Y., & Li, X. P. (2023). Disruption of Iron Homeostasis to Induce Ferroptosis with Albumin‐Encapsulated Pt(IV) Nanodrug for the Treatment of Non‐Small Cell Lung Cancer. Small. https://doi.org/10.1002/smll.202206688
Vancouver
Tian HX, Mei J, Cao L, Song J, Rong D, Fang M, et al. Disruption of Iron Homeostasis to Induce Ferroptosis with Albumin‐Encapsulated Pt(IV) Nanodrug for the Treatment of Non‐Small Cell Lung Cancer. Small. 2023. doi:10.1002/smll.202206688
BibTeX
@article{Tian2023,
author = {Tian, Hui-Xiang and Mei, Jie and Cao, Lei and Song, Jianan and Rong, Dingchao and Fang, Man and Xu, Zhe and Chen, Juan and Tang, Jie and Xiao, Haihua and Liu, Zhaoqian and Wang, Peng-Yuan and Yin, Ji-Ye and Li, Xiang-Ping},
title = {Disruption of Iron Homeostasis to Induce Ferroptosis with Albumin‐Encapsulated Pt(IV) Nanodrug for the Treatment of Non‐Small Cell Lung Cancer},
journal = {Small},
year = {2023},
doi = {10.1002/smll.202206688}
}
EUVIMED